IP Journal of Urology, Nephrology and Hepatology Science

Mirabegron versus tolterodine for the treatment of overactive bladder: A prospective randomized study

Full Text PDF

Article Type : Original Article

Author Details: V. R. Pogula,E. H. Galeti*,S. Davalla

Volume : 4

Issue : 3

Online ISSN : XXXX

Print ISSN : XXXX

Article First Page : 79

Article End Page : 83

Abstract

Objectives: To assess the efficacy of mirabegron and Tolterodine, comparing both drugs by IPSS score at 12th week of intervention.
Materials and Methods: This prospective randomized observational study was conducted in 40 Patients with overactive bladder over 15 months. Patients are divided into two groups, 20 patients (Group-M) receiving Tab Mirabegron 50 mg OD and 20 patients (Group-T) receiving Tab Tolterodine 4 mg OD.
Results: The difference of urine Frequency episodes per 24 hours at the 12th week in Group-M was 2.75 ± 1.41, while that among the Group-T was 1.15 ± 1.04 with a significant p-value < 0>

Conclusion: Mirabegron improved Urgency, the total number of micturition episodes/24 hours, nocturia, IPSS score better than Tolterodine in overactive bladder patients. There is no difference between Mirabegron and Tolterodine in terms of incontinence episodes.

Keywords: Over Active Bladder (OAB); Detrusor Overactivity (DO); International Continence Society(ICS); International Prostate Symptom Score(IPSS)

Doi No:-10.18231